You are here
Efficacy and Safety for Diabetes Specialists
The purpose of this course is to learn how the efficacy and safety of basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy surpasses that of the individual components. Participants will learn how to identify patients who are most likely to benefit from this combination. Practical considerations will be discussed, including tips on how to best manage patients during treatment with basal insulin–GLP-1 receptor agonist combination therapy.
- Intensified treatment goals/options
- Data from phase 3 clinical trials
- Convenience of a single injection
This hallway conversation discusses the safety profile of basal insulin–GLP-1 RA combination therapy. The side-effects of the individual compounds (insulin and GLP-1 RAs) are discussed and compared with the side-effects of combination therapy. The discussion ends with a focus on patient experiences with basal insulin–GLP-1 RA combination therapy.